Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors

Safety Study of MGD009 in B7-H3-expressing Tumors

JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors

A Phase 1 Study to Investigate SNDX-6352 Alone or in Combination With Durvalumab in Patients With Solid Tumors

A Study of ASN007 in Patients With Advanced Solid Tumors

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies

FS118 First in Human Study in Patients With Advanced Malignancies After PD-1/PD-L1 Containing Therapy

A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors

A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors

Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors

A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers

APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies

A Trial of Hu5F9-G4 With Avelumab in Ovarian Cancer

MRTX849 in Patients With Cancer Having a KRAS G12C Mutation

Study of CPI-100 in Patients With Advanced Tumors

A Study of ASP1951 in Subjects With Advanced Solid Tumors

A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors

Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors

INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors

A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors

A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors

Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors

A Phase 1 Study of SY-1365 in Adult Patients With Advanced Solid Tumors

FPA150 in Patients With Advanced Solid Tumors

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors